For decades, prior authorization was the thing that made Medicare Advantage feel restrictive and Original Medicare feel free. As of January 2026, that line has blurred. CMS launched a model that brings prior authorization — assisted by artificial intelligence — into Traditional Medicare for the first time at scale.
It is called WISeR, it is live in six states, and whether you love it or fear it, it signals where federal payment oversight is heading.
1. What WISeR is
The Wasteful and Inappropriate Service Reduction (WISeR) Model, run by the CMS Innovation Center, began January 1, 2026 and runs six years through 2031. It operates in six states — New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington — and applies to Original Medicare, not Medicare Advantage.
For a defined set of services considered prone to low value or misuse — skin and tissue substitutes, electrical nerve stimulators, epidural steroid injections, and similar — providers must either obtain prior authorization or accept pre-payment medical review. Coverage and payment rules do not change; the review step does.
2. The part that’s genuinely new: the reviewers are tech companies
The entities deciding your prior authorizations aren’t your MAC — they’re AI-enabled technology vendors paid on savings.
CMS selected six technology companies — Cohere Health, Genzeon, Humata Health, Innovaccer, Virtix Health, and Zyter — to run the reviews using AI and machine learning, with licensed clinicians making any non-payment determination.
The design choice that has drawn the most scrutiny is the incentive: participants are paid a share of the savings their reviews generate. CMS argues they are incentivized to “get the determination right,” not to deny, and says it will monitor denial rates and penalize or remove participants that underperform. Whether that holds in practice is the open question everyone is watching.
3. “Voluntary” with an asterisk
CMS calls WISeR voluntary, and technically it is — but for providers in the six states furnishing the targeted services, the choice is between submitting a prior authorization or having the claim pulled for pre-payment review. Either way, a review step now sits between the service and the payment.
Standard decisions are due within about three days (two for expedited), an approval is valid for 120 days, and providers with strong track records may eventually earn a “gold-card” exemption. Non-affirmations aren’t directly appealable, but denied claims follow the normal Medicare appeals path, with unlimited resubmissions and peer-to-peer review available.
4. Why this matters beyond six states
A pilot is how CMS finds out whether something scales. Assume this one is a test balloon, not a boundary.
The model is controversial enough that legislation — the Ban AI Denials in Medicare Act — was introduced to prohibit it and any future CMMI prior-authorization model in Traditional Medicare, and the American Hospital Association urged CMS to delay the launch. That opposition is real and unresolved.
But the underlying driver isn’t going away: CMS estimates a large share of health spending is low-value, and Part B spending on skin substitutes alone exceeded $10 billion in 2024. Whether through WISeR or its successor, technology-assisted utilization review in Traditional Medicare is now on the table.
5. What providers and ACOs should do
If you operate in a WISeR state, this is an operational readiness problem: know which of your services are on the list, build the documentation and submission workflow now, and track your affirmation rate toward that gold-card exemption. If you don’t, it is still a strategic signal — the documentation discipline that protects you under risk adjustment is the same discipline that will carry you through utilization review.
For ACOs, there’s a quiet alignment here: WISeR targets exactly the low-value services that total-cost-of-care accountability already penalizes. The overlap is worth building around rather than fighting.
Final Thoughts
WISeR is a small pilot with outsized implications. It tells you that the era of Traditional Medicare paying first and asking questions later is ending, and that AI-assisted review — with all its promise and all its risk — is now part of how the federal government intends to police spending.
As someone who has worked across strategy and the audit side, my read is simple: don’t get distracted by the fight over whether WISeR is good policy. Prepare for the world it’s pointing toward. The documentation and appropriateness disciplines it rewards are ones every value-based organization should already be building.
If you deliver care in a WISeR state — or expect technology-assisted review to spread — the readiness gap is operational, not theoretical. At HealtheNomics I help provider organizations and ACOs build the documentation and appropriateness workflows that turn utilization review from a threat into a manageable step.
Explore the services: https://healthenomics.com/services-2/
Request a strategy conversation: https://healthenomics.com/contact-us/
Connect on LinkedIn: https://www.linkedin.com/in/muhammad-ayoub-ashraf/
Website: https://www.drayoubashraf.com
Watch on YouTube: https://www.youtube.com/@HealtheNomics
